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Abstract
We used a functional complementation approach to identify tumor-suppressor genes and putative therapeutic targets
for ovarian cancer. Microcell-mediated transfer of chromosome 18 in the ovarian cancer cell line TOV21G induced
in vitro and in vivo neoplastic suppression. Gene expression microarray profiling in TOV21G+18 hybrids identified
14 candidate genes on chromosome 18 that were significantly overexpressed and therefore associated with neo-
plastic suppression. Further analysis of messenger RNA and protein expression for these genes in additional ovarian
cancer cell lines indicated that EPB41L3 (erythrocyte membrane protein band 4.1-like 3, alternative names DAL-1 and
4.1B) was a candidate ovarian cancer-suppressor gene. Immunoblot analysis showed that EPB41L3 was activated in
TOV21G+18 hybrids, expressed in normal ovarian epithelial cell lines, but was absent in 15 (78%) of 19 ovarian
cancer cell lines. Using immunohistochemistry, 66% of 794 invasive ovarian tumors showed no EPB41L3 expression
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compared with only 24% of benign ovarian tumors and 0% of normal ovarian epithelial tissues. EPB41L3 was ex-
tensively methylated in ovarian cancer cell lines and primary ovarian tumors compared with normal tissues (P =
.00004), suggesting this may be the mechanism of gene inactivation in ovarian cancers. Constitutive reexpression
of EPB41L3 in a three-dimensional multicellular spheroid model of ovarian cancer caused significant growth sup-
pression and induced apoptosis. Transmission and scanning electron microscopy demonstrated many similarities
between EPB41L3-expressing cells and chromosome 18 donor-recipient hybrids, suggesting that EPB41L3 is the
gene responsible for neoplastic suppression after chromosome 18 transfer. Finally, an inducible model of EPB41L3
expression in three-dimensional spheroids confirmed that reexpression of EPB41L3 induces extensive apoptotic cell
death in ovarian cancers.
Neoplasia (2010) 12, 579–589
Introduction
In 1978, Stanbridge and Wilkinson showed that the fusion between
HeLa cervical carcinoma cells and normal diploid fibroblasts created
somatic cell hybrids with a stable karyotype and a suppressed tumori-
genic phenotype [1]. The phenotypic changes were later attributed to
the effects of normal copies of human chromosomes from the normal
fibroblasts, functionally complementing the genetic background of the
HeLa cells [2]. These findings formed the basis of a methodological
development, microcell-mediated chromosome transfer (MMCT),
which enables the introduction of individual human chromosomes into
cancer cells and, subsequently, the localization and identification of
genes associated with a multitude of biologic mechanisms including cel-
lular senescence, immortalization, and tumor suppression [3].
Since its development, MMCT has been used extensively as an
approach to improve our understanding of tumor development. In-
vestigators have found functional evidence for several loci scattered
throughout the genome that induce neoplastic suppression in a variety
of tumor types [4–8]. However, progress in taking these studies forward
to the stage of identifying the genes responsible has been hampered by
the limited resolution of the methodology. It has often required detailed
genomic and functional mapping to reduce the chromosome of interest
down to a few megabases, and this frequently proves to be a challenging
and lengthy process. The advent of gene expression microarray tech-
nologies has enabled researchers to sidestep this bottleneck, and a few
studies that combine MMCT analysis with gene expression profiling
have now been published, leading to the identification of plausible
functional candidate genes for different diseases [9–11].
Some studies have used MMCT to identify chromosomes and sub-
chromosomal regions that cause neoplastic suppression in ovarian cancer
cells [12–15]. However, these studies have yet to find definitive evidence
of a role for any of the candidate genes subsequently identified in the
development of ovarian cancers. Generally, the mechanisms that under-
lie ovarian tumor development remain poorly understood, and this con-
tinues to have a major impact on clinical intervention strategies for
tackling the disease. Despite improvements in cytoreductive surgery
and the initial good response of patients to platinum-based chemothera-
pies, there have been few improvements in the survival rates for patients
diagnosed with ovarian cancer for more than three decades; approxi-
mately 65% of patients will die within 5 years of their diagnosis [16].
There are many reasons for the poor survival rates. Significantly, most
patients are diagnosed with advanced stage disease; but also, there are
no reliable prognostic markers for predicting clinical response and guid-
ing treatment and no novel molecular targets expressed in ovarian tumors
that have led to the development of new therapies. To identify chromo-
some regions that are involved in the development of ovarian cancer, we
recently reported using MMCT in ovarian cancer cell lines for seven
chromosomes (4, 5, 6, 13, 14, 15, and 18) that we found to be frequently
deleted in primary ovarian cancers [17,18]. We found that chromo-
some 18 functionally suppresses the neoplastic phenotype of ovarian
cancer cell lines [18]. Here we describe the identification and evaluation
of 14 candidate genes located on chromosome 18 that are activated in
MMCT+18/cancer cell line hybrids. For one of these candidate genes
(erythrocytemembrane protein band 4.1-like 3,EPB41L3), further func-
tional evaluation in primary ovarian tumors and in three-dimensional
models of ovarian cancer provided additional evidence supporting a role
of EPB41L3 in ovarian cancer development.
Materials and Methods
Microcell-Mediated Monochromosome Transfer
MMCTwas performed in the TOV21G cancer cell line as previously
described [18,19]. TOV21G is an epithelial ovarian cancer cell line de-
rived from a clear cell ovarian carcinoma. Briefly, the recipient ovarian
cancer cell line was fused with mouse (A9):human monochromosome
donor cell lines carrying the selectable fusion gene marker hygromycin
phosphotransferase. MMCT hybrids were selected from post fusion cells
in medium supplemented with hygromycin B (Calbiochem, Merck
Chemicals Ltd, Nottingham, UK). The in vitro phenotype of recipient-
donor hybrids was evaluated using anchorage-dependent and -independent
growth assays and invasion through aMatrigel [20]. In vivo tumorigenicity
was assayed after intraperitoneal injection of ∼2.5 × 106 cells in immuno-
suppressed mice as previously described [20].
Genomic Mapping of Hybrids
The chromosome 18 content of hybrids and recipient cell lines was
evaluated usingmetaphase chromosome painting. Fluorescentwhole chro-
mosome paints (Q-Biogene, Cambridge, UK) were used to detect the
transferred chromosome by in situ hybridization using standard protocols.
A mouse pan-centromeric probe (Q-Biogene) was used to detect any
mouse DNA transferred; none was present in any of the hybrids analyzed.
Fifteen metaphase spreads were scored for each cell line. Microsatellite
analysis of 18 markers spanning chromosome 18 (http://www.gdb.org/)
was used to determine whether the transferred allele was present. Array
comparative genomic hybridization analysis was performed using a
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whole genome tiling-path consisting of 32,450 BAC clones (http://www.
instituteforwomenshealth.ucl.ac.uk/trl/microarray_facility.html). Fluo-
rescently labeled DNA of chromosome hybrid cell lines was hybridized
against the parental cell lines. DNA samples were labeled with Cy3 or
Cy5using theBioprimeTotal LabelingKit (Invitrogen, Paisley,UK). Slides
were scanned using an Axon 4000B laser scanner (Genepix, Molecular
Devices, Sunnyvale, CA) at a 5-μm resolution. Raw fluorescence data were
extracted using “BlueFuse” software (BlueGnome, UK) and normalized
using the MANOR and LIMMA packages [21]. The log2 of fluorescence
ratios (M ) were plotted against genome location usingBACclone locations
derived from the National Center for Biotechnology Information Human
Genome build 36 (HG18).
Differential Gene Expression Analysis
Total RNA isolated from cell lines was quality control tested using a
Nano assay with an Agilent Bioanalyzer 2100 (Agilent Technologies,
Inc, Santa Clara, CA). RNA was converted into digoxigenin-labeled
complementary RNA and hybridized to a human genome microarray
system (Human Genome Survey Microarray Version 2; Applied Bio-
systems, Foster City, CA), which contains 32,878 probes for the inter-
rogation of 29,098 genes. Gene expression profiles were generated in
triplicate for each cell line. Data analysis was performed using Applied
Biosystem’s 1700 ArrayExpress software, Spotfire DecisionSite for Func-
tional Genomics software (Goteborg, Sweden), and R version 1.9.1.
Probes that were deemed undetectable were excluded from the final
analyses if they had a signal-to-noise ratio less than 3. An analysis of vari-
ance was used to generate P values for statistical differences between
probes. P values were adjusted for multiple comparisons as described
by Benjamini and Yekutieli [22]. Genes were statistically different be-
tween groups if they had an adjusted P < .01 and an average fold change
difference greater than 1.6. Gene ontology analysis was performed using
the Panther classification system (http://www.pantherdb.org).
Real-time Polymerase Chain Reaction Analysis
Total RNAwas extracted and analyzed by real-time reverse transcription–
polymerase chain reaction (PCR) using optimized TaqManGene Expres-
sion assays (Applied Biosystems). The efficacy of 18S as an endogenous
control was examined using the 2−ΔC t method.
Immunoexpression Analysis
Immunoblot analysis was performed for cell lines using two pri-
mary monoclonal antibodies that recognize the EPB41L3 protein,
anti–Dal-1 monoclonal antibody from Imgenex (San Diego, CA) and
anti–Dal-1 monoclonal antibody from Abcam (Cambridge, UK). Cell
lysates were separated by SDS-PAGE, transferred to Immobilon P mem-
brane (Millipore, Watford Hertfordshire, UK), probed with the primary
antibody and an HRP-conjugated secondary antibody. Immunoreactive
bands were visualized with the enhanced chemiluminescence system
(NEN Life Sciences, Boston, MA). For immunohistochemistry analysis,
tissue sections were incubated with a rabbit anti-EPB41L3 polyclonal
antibody (1:1500 dilution, kindly donated by Dr I. Newsham) using
standard protocols [23]. The malignant and nonmalignant tissues were
scored for EPB41L3 by assessing the site of positive staining in the
tissue. Semiquantitative scoring criteria were used for immunohisto-
chemistry; both staining intensity and positive areas of staining were
recorded. We scored EPB41L3 positive staining calculated from the
proportion of immunopositive neoplastic cells in the specimen (0, nega-
tive [<5%of positive cells]; 1, weak [5%-20%]; 2,moderate [20%-50%];
3, strong [>50%]).
DNA Methylation Analysis
Cell line analyses. Quantitative DNA methylation analysis was
performed in ovarian cancer and normal ovarian epithelial cell lines
using the MassARRAY EpiTYPER (Sequenom, San Diego, CA) after
DNA bisulfite treatment and matrix-assisted laser desorption ionization
time-of-flightmass spectrometry analysis.Mass spectra were acquired by
using a MassARRAY Compact MALDI-TOF, and the spectra’s meth-
ylation ratios were generated by the Epityper software v1.0 (Sequenom).
The EPB41L3 promoter was analyzed in three PCR amplicons, de-
signed using EpiDesigner software (Sequenom). In total, 154 CpG sites
in EPB41L3 were analyzed.
Primary tissue analyses. A total of 45 invasive ovarian cancer tumor
tissue samples (of various histologic subtypes) and 16 normal tissue sam-
ples (endometrial, peritoneal, and fallopian tube tissues) were analyzed
for 20,000 probes using the Illumina Infinium (Illumina, San Diego,
CA) “genome-wide” panel after extraction and bisulfite conversion of
DNA. Tissue samples were collected from Duke University and the
University of Southern California; the analysis had ethical committee ap-
proval. All data were analyzed using Genetrix/SB version 3.3 (Epicenter
Software, Alhambra, CA). The mean methylation values between the
tumor and normal samples for each of these probes were compared using
a parametric t test.
Expressing EPB41L3 in Ovarian Cancer Cell Lines
For continuous expression, EPB41L3 complementary DNA (cDNA)
was cloned into a pBMN expression vector and transfected into three
epithelial ovarian cancer cell lines: TOV21G, SCOV3, and INTOV2
using FuGENE 6 Transfection Reagent (Roche, Welwyn, UK). Briefly,
106 cells were transfected with the gene expression vector or a con-
trol vector expressing the GFP reporter gene (Orbigen, San Diego,
CA). Selection was performed using 500 μg/ml geneticin (Sigma-
Aldrich, St Louis, MO), and cells expressing the plasmids were subcul-
tured by ring cloning. Stably transfected cell lines expressing EPB41L3
were established as multicellular spheroids by culturing cells in 1%
agarose-coated 24 multiwell plates. Spheroids were visualized using an
inverted microscope to calculate spheroid size and volume. The pro-
jected area, A and perimeter P, for each spheroid were measured using
IMAGE J software (http://rsbweb.nih.gov/ij/). Spherical volume and
geometric mean diameter of each spheroid were calculated as previously
described [24].
Conditional EPB41L3 Expression
The Ecdysonemuristerone–induced system (gift from IreneNewsham)
was used to generate an inducible TOV21G-EPB41L3 expressing cell
line. Transfection of the retinoid-X receptor containing vector (pVgRXR)
was followed by the pIND- EPB41L3 vector, and the doubly transfected
clones were selected with 35 μg/ml zeocin (Invitrogen) and 600 μg/ml
geneticin (Sigma). Approximately 30 clones were screened by EPB41L3
specific fluorescence activated cell sorting (FACS) analysis for controlled
inducible expression after 48 hours of 1 μMmuristerone (Invitrogen) ex-
posure. The clones generated from the inducible expression of EPB41L3
in ovarian cancer cells were screened for EPB41L3 protein expression by
FACS analysis to identify a clone expressing high levels of EPB41L3
(>65% of cells expressed the protein) for use in downstream experiments.
Multicellular spheroids were formed by culturing cells in poly-HEMA
(Sigma)–coated vessels as previously described [25,26].
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Assaying Apoptosis and Live/Dead Proportionality in Spheroids
Apoptosis was measured using the Annexin-V–FLUOS staining kit
(Roche) according to the manufacturers instructions. Briefly, 106 cells
were washed with PBS and were stained with annexin Vand propidium
iodide for 15 minutes at room temperature and analyzed using a flow
cytometer (Becton and Dickinson, Oxford, UK). Live/dead assays were
performed after induction of EPB41L3 expression using a commercially
available live/dead viability and cytotoxicity assay (Molecular Probes,
Invitrogen). Spheroids were stained with 2 mM calcein and 4 mM
ethidium homodimer 1 for 30minutes at room temperature, and image
capture was performed using a confocal microscope (Ultraview; Perkin
Elmer, Cambridge, UK).
Transmission and Scanning Electron Microscopy
Spheroids were washed with phosphate-buffered saline and fixed
with 2% paraformaldehyde, 1.5% glutaraldehyde in 0.1 M cacodylate
buffer, pH 7.3, then washed in 0.1 M cacodylate buffer and postfixed
with 1% osmium tetroxide in 0.1 M cacodylate buffer. Finally, spher-
oids were washed in 0.1 M cacodylate buffer before being stained with
0.5% uranyl acetate and dehydrated with ethanol. For transmission
electron microscopy (TEM), spheroids were embedded in agar resin,
sectioned, and examined on a JEOL 1010 TEM microscope ( Jeol
Ltd, Tokyo, Japan). For scanning electron microscopy (SEM), samples
were postfixed with 1% osmium tetroxide in 0.1 M cacodylate buffer
pH 7.3 before dehydrating with ethanol, critical point drying, mount-
ing on carbon stubs, and coating with gold before viewing under a
JEOL 7401 series FEGSEM (Jeol Ltd).
Results
Identifying Candidate Tumor-Suppressor Genes on
Chromosome 18
We have previously shown that chromosome 18 induces neoplastic
suppression of the epithelial ovarian cancer cell line TOV21G both
in vitro and in vivo (Table W1) [18,27]. To identify candidate tumor-
suppressor genes located on chromosome 18, we used gene expression
microarrays to compare 29,098 different genes between the ovarian
cancer cell TOV21G and two TOV21G+18 hybrids. The aim was to
identify genes that showed an increase in expression in TOV21G+18
hybrids, which may suggest that they are functionally activated and
responsible for the suppression phenotype. We found 14 chromosome
18 genes that were significantly overexpressed in both TOV21G+18
hybrids compared with the TOV21G cell line (Table 1). The locations
of these genes with respect to mapping data for chromosome 18 in the
hybrids are illustrated in Figure 1A. Semiquantitative RT-PCR analysis
of 10 of these genes was used to validate the results of gene expression
microarray analysis and showed the same trend in expression change
for all 10 genes compared with the microarray expression data (data
not shown).
For the 14 candidate genes, we reviewed the evidence of a role in
cancer based on their known or putative function and any experimental
data from previously published studies. On the basis of this analysis,
we restricted the list of plausible candidates to 11 genes, which we eval-
uated further by analyzing gene and protein expression (if antibodies
were available) in a panel of 19 ovarian cancer cell lines and 3 normal
ovarian epithelial cell lines (Table 1). These analyses suggested that
one candidate gene in particular, EPB41L3 (the erythrocyte membrane
protein band 4.1-like 3 gene or alternative nomenclature DAL-1), at
18p11.32 is a candidate ovarian cancer-suppressor gene.
Evaluating EPB41L3 as an Ovarian Cancer-Suppressor Gene
Expression microarray analysis indicated that EPB41L3 was more
than 50-fold overexpressed in TOV21G+18 hybrids compared with its
expression in TOV21G cells (Figure 1B). Microsatellelite analysis con-
firmed that this gene had been transferred into both TOV21G hy-
brids (data not shown). The high level of increased expression in the
TOV21G+18 hybrids suggested that the gene had been activated as result
of the chromosome transfer. Consistent with this, most genes flank-
ing EPB41L3 showed only minor variation in the levels of differential
gene expression between TOV21G and TOV21G+18 cells (Figure 1A).
Table 1. Candidate Ovarian Cancer Tumor Suppressor Genes Identified by Differential Gene Expression Analysis of the TOV21G Cell Line and the MMCT Hybrids TOV21G+18.1 and TOV21G+18.2.
Gene Differential Microarray
Expression Analysis
Cancer Cell Line
Expression
Putative Function* References†
FC‡ P§ RNA¶ Protein#
EMILLIN 2 11.67 3.00e−03 36% 15% Extracellular matrix glycoprotein cell adhesion overexpressed in ovarian tumors [15]
KNTC2 0.03 8.11e−05 21% 10% Mitotic spindle check protein overexpressed in tumors [4]
EPB41L3 50.2 8.11e−06 89% 79% Tumor suppressor: underexpressed in lung, breast, and prostate cancers [7,8,9]
RALBP1 2.43 .001 ND NA Membrane traffic protein; overexpressed in ovarian, lung cancer [2]
CDH2 16.6 .003 52% 70% Cadherin, cell adhesion-wnt signaling pathway; overexpressed in epithelial tumors [12]
SNRPD1 3.5 .0003 ND NA Small nuclear riboprotein-promotes snRNP assembly, messenger RNA splicing factor [6]
KIAA1632 8.6 .0002 ND NA Molecular function unclassified NR
CCDC5 1.9 .009 52% 0% Regulation of spindle function, cell cycle control [5]
MYO5B 6.3 .001 21% NA actin binding motor protein, methylated in leukemias [11]
TCF4 145 6.36e−06 10% 0% Transcription factor, cell proliferation-differentiation [10]
ZNF532 0.1 3.92e−06 52% NA KRAB box transcription factor SR [14]
C18ORF22 3 4.36e−06 ND NA Molecular function unclassified NR
SDCCAG33 2.9 4.97e−07 57% NA Zinc finger transcription factor, colon cancer antigen [3,14]
CYB5 2.1 .004 ND NA Steroid metabolism [3]
NA indicates antibody not available; ND, RT-PCR not done.
*Putative gene function and role in carcinogenesis: information obtained from Panther Ontology and Genecards databases.
†References used to evaluate the significance of each candidate gene are provided in Supplementary Information 1. NR indicates no reference; SR, supplementary reference number.
‡Average fold change overexpression in two MMCT hybrids compared with the parental ovarian cancer cell line.
§Statistically significant difference in expression between two MMCT hybrids and the parental ovarian cancer cell line.
¶Semiquantitative RT-PCR analysis comparing the average gene expression of three normal ovarian epithelial cell lines (normalized to the endogenous control gene 18S) and gene expression in each of 19
different epithelial ovarian cancer cell lines. The figure given for each gene represents the proportion of ovarian cancer cell lines that show reduced expression compared with normal cell expression.
#The proportion of ovarian cancer cell lines that showed complete absence of protein expression (measured by immunoblot analysis) for genes where antibodies were available.
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Immunoblot analysis confirmed the absence of EPB41L3 protein in
TOV21G cells and a strong expression in both of the TOV21G+18
hybrid cell lines (Figure 1C ). Three normal ovarian surface epithelial
cell lines also showed high levels of EPB41L3 expression.
EPB41L3 protein expression was further evaluated in ovarian cancer
cell lines and tissues from primary invasive epithelial ovarian cancers,
benign epithelial ovarian tumors, and normal ovarian epithelium by
Western blot analysis and immunohistochemistry. EPB41L3 expression
was absent in 15/19 ovarian cancer cell lines (79%; Figure 2A). Immuno-
histochemical staining of 794 invasive and 33 benign tumors distributed
across tissue arrays from three different studies showed no identifiable
EPB41L3 expression in 65% of all invasive tumors and minimal, partial
or complete expression in 20%, 10%, and 5% of these tumors, respec-
tively (P trend = .01). When tumors were stratified by histologic sub-
type, clear cell, serous, mucinous, and endometrioid subtypes showed
the most frequent loss of EPB41L3 expression (69%, 66%, 61%, and
Figure 1. (A) Genomic mapping and candidate gene identification in TOV21G+18 hybrids confirm the transfer of chromosome 18 material
in parental cancer cell lines. (i) Metaphase fluorescence in situ hybridization (FISH) using a chromosome 18 paint of TOV21G cells (top panel)
and TOV21G+18 cells (bottom panel) confirms the transfer of a single additional copy of chromosome 18 (green fluorescent staining) in the
hybrid cells. (ii) Microarray CGH analysis confirms the results of FISH and provide more detailed mapping information of TOV21G+18 cells.
Microarray CGH profiles show copy number difference between parental and hybrid cell line for a tiling path of bacterial artificial chromo-
somes (BACs) spanning the length of chromosome 18. Green spots indicate single copy number gain. Mapping showed the same regions
transferred for both hybrids used in expression analysis of each cell line. (iii) The location of genes on chromosome 18 identified by differ-
ential gene expressionmicroarray analysis of the TOV21G cancer cell line compared with twoMMCT hybrids. The candidate gene EPB41L3,
which was taken forward for further analyzes, is highlighted in red. (iv) The expression fold change for the EPB41L3 gene and flanking genes
in TOV21G cells suggest the activation of EPB41L3. (B) Volcano plot showing the gene expression data from chromosome 18 in TOV21G+18
hybrids compared with TOV21G cancer cells. The color point showing the magnitude of fold change in EPB41L3 gene expression (x-axis),
coupledwith statistical significance (y-axis:−log10 of the P value). (C) Immunoblot analysis using a EPB41L3monoclonal antibody suggests
a lack of expression in TOV21G cells but strong expression in both TOV21G+18 hybrids (MMCT18G1 and MMCT18G2), suggesting that
EPB41L3 is activated in hybrid cells. EPB41L3 is also highly expressed in two primary normal ovarian surface epithelial cell cultures (NOSE11
and NOSE19) and in an immortal ovarian surface epithelial cell line (IOSE4); 110 kDa is the expected and observed size of the EPB41L3
protein band.
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57%, respectively). In contrast, there was no evidence of loss of EPB41L3
expression in 55% of benign tumors and in all five normal ovarian epi-
thelial tissue samples. These data are illustrated in Figure 2, B and C (see
also Table W2).
Studies in other cancers suggest that methylation of the EPB41L3
promoter is a common mechanism by which the gene is downregulated
during tumor development. Therefore, we examined the methylation
status of EPB41L3 in 16 ovarian cancer cell lines and 8 normal ovarian
epithelial cell lines using a semiquantitative approach that enabled us to
examine themethylation status at all CpG sites for the gene (Supplemen-
tary Information 2). Most ovarian cancer cell lines, including TOV21G,
showed extensive methylation at the EPB41L3 locus, whereas normal
ovarian epithelial cells showed hypomethylation relative to cancer cells
(Figure 2D). We also analyzed the methylation status of EPB41L3 and
other genes in the flanking regions in 45 primary invasive ovarian tumors
and 16 normal primary tissue samples (endometrium, peritoneum, and
fallopian tube). This was part of a genome-wide methylation analysis of
approximately 20,000 probes (data not shown). Of the 32 probes from
the 7.9-Mb region surrounding EPB41L3, which contains 22 genes,
only 2 probes showed a statistically significant difference in the mean
methylation values between tumor and normal samples: RALBP1 (P =
.016) and EPB41L3 (P = .00004). When all probes located on chromo-
some 18 (n = 304) were analyzed and a false discovery rate of 0.05 was
applied (equivalent to P = .003), EPB41L3was one of only 19 probes that
showed a statistically significant difference in mean methylation values.
Functional Effects of Reexpressing EPB41L3 in Ovarian
Cancer Cells
A full-length normal EPB41L3 cDNA, cloned into a pBMN expres-
sion vector, was transfected into three ovarian cancer cell lines: TOV21G
(TOV21G+EPB41L3), SCOV3 (SCOV3+EPB41L3), and INTOV2
(INTOV2+EPB41L3). After confirming the reexpression of EPB41L3
in TOV21G, we evaluated the effects on anchorage-dependent and
-independent growth and compared these phenotypes with those of the
same cells transfected with an empty pBMN vector expressing GFP
(TOV21G+GFP, SCOV3+GFP, and INTOV2+GFP). EPB41L3-expressing
cells formed significantly fewer colonies than GFP-transfected cells and
untransfected cells. The colonies that did form after EPB41L3 trans-
fection were substantially more disparate and showed markedly de-
creased anchorage-dependent and -independent growth (Supplementary
Information 3).
We established three-dimensional multicellular spheroids of TOV21G,
INTOV2, and SCOV3 ovarian cancer cell lines, of the GFP- and
EPB41L3-expressing forms of these cell lines and of TOV21G+18 hy-
brids (Supplementary Information 3). Macroscopically and micro-
scopically, the spheroids that formed from TOV21G, INTOV2, and
SCOV3 cell lines and from GFP-expressing cells shared similar phe-
notypic characteristics, with no significant differences in their size. In
contrast, spheroids formed from TOV21G+18 hybrids and EPB41L3-
transfected cancer cell lines were significantly smaller compared with
parental cell lines, consistent with the postulated tumor-suppressive ef-
fects of EPB41L3 (P > .0001 for size and P > .0001 for volume; Figure 3,
A and B). The structural and morphologic features of parental cell lines
also changed substantially after EPB41L3 transfection, shown by SEM
and TEM (Figure 3C). For example, TOV21G cells revealed structures
consistent with their epithelial origin (secretion of an extracellular ma-
trix; tight junctions, desmosomes, and microvilli; lumens forming within
spheroids). However, spheroids established from TOV21G+18 and
TOV21G+EPB41L3 cells showed less cell aggregation and membrane inter-
actions (smooth contours), clear signs of increased apoptosis in surface cells,
large cell surface protrusions (including filopodia and microspikes), and
degenerating cell membranes. FACS analysis for annexin V confirmed that
the transfer of chromosome 18 or reexpression of EPB41L3 in TOV21G,
INTOV2, and SCOV3 cells induces apoptosis (Figure 3D).
Finally, we evaluated the effects of inducing EPB41L3 expression
after the formation of spheroids using an Ecdysone muristerone–
inducible system. We generated an inducible TOV21G+EPB41L3/ECD
cell line and used FACS analysis to confirm EPB41L3 expression after
muristerone induction (data not shown). A fluorescent live/dead assay
was used to evaluate apoptosis in spheroids. Ten days after EPB41L3
induction, the ratio of “live” to “dead” (apoptotic) spheroids was sig-
nificantly lower than it was for the same cells without EPB41L3 induc-
tion (1:3 vs 6:1, P < .002; Figure 3E).
Discussion
Using a functional complementation approach, we have identified
EPB41L3 as a candidate tumor-suppressor gene for ovarian cancer. The
gene is extensively methylated in ovarian cancer cell lines and primary
Figure 2. Evaluating EPB41L3 status in primary ovarian cancers, ovarian cancer cell lines, and normal ovarian epithelial cell lines and tissues
by immunohistochemistry and methylation analyses. (A) Immunoblot analysis for EPB41L3 in ovarian cancer cell lines shows absence of
expression in 15 (79%) of 19 cell lines. (B) Illustration of EPB41L3 expression analyzed in 794 invasive ovarian cancer specimens (stratified
by histologic subtype) and 33 benign ovarian tumors. Staining values: 0, less than 5% of neoplastic cells stain positive; 1, 5% to 20%; 2,
20% to 50%; 3, more than 50%. Immunohistochemistry was performed for invasive ovarian cancers and benign tumors established as
tissue arrays taken from three ovarian tumor tissue collections: the Danish MALOVA study (488 ovarian tumors) [23], the Derby City Hos-
pital tumor array (263 ovarian tumors), and the Newcastle ovarian cancer tissue micro array (160 invasive tumors) [41]. Normal primary
epithelial tissues and additional invasive ovarian tumors were provided by the University College London Hospital ovarian tumor tissue
biobank. (C) Examples of immunohistochemical staining with EPB41L3. Where we observed EPB41L3 staining, it suggested that EPB41L3
protein expression occurs uniformly throughout the cytoplasm and in cell membranes of both tumor and normal cells. All panels are 200×
magnification: (i) 100% expression in an endometrioid ovarian cancer, (ii) 90% expression in a serous ovarian cancer, (iii) 0% expression
in an endometrioid ovarian cancer, (iv) 50% expression in an endometrioid ovarian tumor, (v) 10% expression in a serous ovarian tumor
(vi), 20% expression in a serous ovarian cancer, (vii) 30% expression in an endometrioid ovarian cancer, (viii) 100% expression in normal
ovarian surface epithelial cells, and (ix) 100% expression in normal ovarian epithelial cells in an inclusion cyst. IC indicates inclusion cyst;
NOE, normal ovarian epithelium; NSE, negative staining epithelium; PSE, positive staining epithelium. (D) Heat map illustrating methylation
analysis of the EPB41L3 promoter in normal ovarian surface epithelial cell lines and 16 ovarian cancer cell lines. Each feature represents the
methylation status at a CpG dinucleotide in the promoter region. The darker the feature, the more hypermethylated the CpG. Combining
the data, for all CpGs, 74% of CpGs showed greater than 60% methylation in ovarian cancer cell lines; only 1% of CpGs were more than
60% methylated in the normal ovarian epithelial cell lines.
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tumor tissues compared with normal epithelial ovarian cells and pri-
mary normal tissues, EPB41L3 protein expression is completely lost
in 65% of all primary invasive ovarian tumors and in 79% of ovarian
cancer cells lines, and reexpression of the gene in three-dimensional
ovarian cancer cell line models causes growth suppression and increased
apoptosis. To our knowledge, this is the first report linking EPB41L3 to
ovarian carcinogenesis.
In the past, MMCT has been successful at identifying chromosome
and subchromosomal regions that are associatedwith a disease phenotype
or functional mechanism but rarely has definitive evidence for a specific
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gene responsible for the observed phenotype been shown. Largely, this
is because of the scale of the task in fine mapping the chromosome re-
gion of interest and then evaluating several putative candidate genes. The
task is made greater still because there are several mechanisms by which
the function of a gene can be abrogated (e.g., coding sequence mutation,
promotor methylation, gene deletion), and evaluating each possible
mechanism is a major challenge. In the current study, the approach we
used identified a relatively small series of candidate genes that were asso-
ciated with neoplastic suppression, caused by chromosome 18 transfer
into an ovarian cancer cell line. Additional analysis based on known
function and the molecular analysis of several ovarian cancer cell lines
suggested that EPB41L3 was the strongest candidate; but it remains a
possibility that one or more of the other identified genes, or an as yet
unidentified gene, is the real cause of neoplastic suppression. Following
up on one or several of the other candidate genes we identified will
require additional and extensive functional analyses to establish if they
have a role in ovarian carcinogenesis.
Some studies have successfully identified the gene responsible for the
phenotype after MMCT, which shows the power of this methodologi-
cal approach. For example, two recent MMCTstudies have found two
genes, cblD on chromosome 2q23.2 and cblF on chromosome 6q13
that are involved in vitamin B12 metabolism [28,29]. In our study,
the evidence that EPB41L3 is the chromosome 18 gene that causes
neoplastic suppression in TOV21G is compelling. The phenotypic
features of EPB41L3-expressing cells and TOV21G+18 hybrids are
remarkably similar in the macroscopic and microscopic appearance
of multicellular spheroids and in their growth characteristics and apop-
totic phenotype. The analysis of EPB41L3 in cancer cell lines and pri-
mary tumors provides strong evidence that EPB41L3 is an ovarian
cancer-suppressor gene. Immunohistochemistry analysis of more than
800 ovarian tumors found that EPB41L3 is downregulated in approxi-
mately two-thirds of all major histologic subtypes of ovarian cancer
but is strongly expressed in normal ovarian epithelium. It is uncommon
to find a molecular marker that shows a similar pattern of expression in
all the major ovarian cancer subtypes. A recent study by Kobel et al.
[30] analyzed 21 candidate tissue biomarkers in 500 invasive ovarian
tumors and found extensive variation in the patterns of expression
between high-grade serous, clear cell, endometrioid, and mucinous
ovarian carcinomas for almost all markers tested. However, immuno-
histochemistry alone does not provide sufficient evidence that a gene is
essentially involved in tumor development. It is possible that EPB41L3 is
merely a marker for a functionally relevant biologic mechanism or path-
way involved in ovarian cancer progression. Therefore, it was important
to identify the mechanism by which EPB41L3 was downregulated. Pre-
vious studies have shown that EPB41L3 is hypermethylated in non–
small cell lung cancers, hepatocellular carcinomas, meningiomas, renal
clear cell carcinomas, and prostate carcinomas [31–34]. Another study
suggests that functionally significant somatic mutations of EPB41L3
are probably rare [35]. We tested and found evidence for extensive
EPB41L3 promoter hypermethylation in ovarian cancer cell lines and
primary ovarian tumors compared with normal cells, suggesting that this
is the likely cause of EPB41L3 down-regulation in ovarian tumors.
EPB41L3 expression was more prominent in benign ovarian tumors,
and all normal ovarian epithelial cells analyzed showed strong expres-
sion. This possibly indicates that loss of EPB41L3 expression is a late
rather than an initiating event in ovarian cancer progression. This is
supported by in vivo data, which show that mice deficient for EPB41L3
develop normally and are fertile. Rates of cellular proliferation and
apoptosis in brain, mammary, and lung tissues from the EPB41L3 null
mice were similar to those in wild-type mice, and there was no evi-
dence that null mice were susceptible to tumor development [36].
However, when EPB41L3-null mice are crossed with TRAMP mice,
which express SV40 in the prostate, mice have a much greater propen-
sity to develop aggressive, spontaneous prostate carcinomas compared
with TRAMP mice alone [37]. The known functions of EPB41L3 are
also consistent with a role for the gene in the later stages of tumor devel-
opment. EPB41L3 is a member of the band 4.1 family of cytoskeletal
proteins, which includes ezrin, radixin, moesin, and merlin. These pro-
teins participate in organizing the actin cytoskeleton and ensure stable
cell-cell adhesion. It is well known that interrupting the mechanisms
that regulate cell adhesion leads to increased growth, invasion, and
metastasis in tumor cells; these features are characteristic of the pheno-
typic changes we observed in the current study after transferring chromo-
some 18 and, subsequently,EPB41L3 into ovarian cancer cells. Two other
studies have shown that reexpressing EPB41L3 in the MCF7 breast can-
cer cell line both increases cell adhesion and induces apoptosis [38,39].
We used an in vitro three-dimensional modeling approach to test the
functional effects of reexpressing EPB41L3 in ovarian cancer cell lines
Figure 3. Functional effects of reexpressing EPB41L3 cDNA in the TOV21G ovarian cancer cell line. (A) Spheroid formation in (i) TOV21G cells,
(ii) TOV21G+GFP cells, (iii) TOV21G+GFP cells under fluorescent microscopy showing expression of green fluorescent protein, (iv) TOV21G+18
hybrid, and (v) TOV21G+EPB41L3 cells. (B) Analysis of average spheroid volume and area for six replicates in two independent experiments in the
ovarian cancer cell lines TOV21G, INTOV2, and SCOV3; their respective GFP-transfected lines TOV21G+GFP, INTOV2+GFP, and SCOV3+GFP;
EPB41L3-expressing spheroids TOV21G+EPB41L3, INTOV2+EPB41L3, and SCOV3+EPB41L3; and the chromosome 18–transferred spheroids,
TOV21G+18. EPB41L3-expressing and chromosome 18–transferred spheroids show significantly reduced size and volume compared with
parent and GFP-expressing cancer cell lines. (C) SEM/TEM analysis of TOV21G spheroids: (i) TEM analysis of TOV21G spheroids shows a
well-defined compact structure. (ii) TEM analysis of TOV21G+EPB41L3 spheroids shows a more diffuse structure. (iii) At higher magnification,
TOV21G spheroids display a smooth outer surface, indicative of good cellular interactions and secretion of extracellularmatrix. (iv) In contrast,
TOV21G+EPB41L3 spheroids show degenerating cell membranes, characteristic of apoptosis. (v) Electron micrographs of sections of TOV21G
spheroids show polarized cells and the formation of lumens (L) (a characteristic of epithelial cells). (vi) Micrographs TOV21G+EPB41L3 sections
show chromatin condensation, large numbers of phagocytosomes, and vacuoles (black arrows), which are characteristics of apoptotic cells.
(vii, viii) Striking similarities between TOV21G+18 and TOV21G+EPB41L3 spheroids, which include large cell surface protrusions (filopodia and
microspikes). (D) FACS analysis for simultaneous staining of annexin V (apoptotic cells) and propidium iodide (necrotic cells) show increased
levels of apoptosis in TOV21G+18 hybrids and EPB41L3-expressing cells compared with untransfected TOV21G, INTOV2, and SCOV3 cell
lines and their respective GFP-expressing cells. (E) Inducing EPB41L3 expression in TOV21G spheroids. Fluorescent live-dead viability assays
compare the proportion of live (viable) spheroids (green fluorescence) and dead (apoptotic) spheroids (red fluorescence). (i) Two days after
induction of EPB41L3, more than 90% of spheroids are viable (ratio of live to dead spheroids is 15:1). (ii) Ten days after induction, more than
70%of the spheroids had undergone apoptosis (live-dead ratio 1:3). (iii) Some apoptosis was also seen in noninduced spheroids after 10 days
(<20%; live-dead ratio 6:1). (v) Higher magnification shows live-dead spheroids 10 days after induction of EPB41L3 expression.
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because we have previously shown that three-dimensional culture mod-
els are much more reflective of the in vivo phenotype than traditional
two-dimensional monolayer cultures [25,26]. To our knowledge, this
is the first time that such an approach has been used to study the func-
tional effects of expressing individual genes in cancer cells. The data
provide support for the suppressive effects of EPB41L3 reexpression
in ovarian cancer cells and show that this expression induces apoptosis
and restricts cell adhesion; spheroids generated from three EPB41L3-
expressing ovarian cancer cell lines were visibly less compact than spher-
oids formed from the cancer cells without EPB41L3. These studies also
suggest that this three-dimensional system could be suitable for evalu-
ating novel therapeutic targets for ovarian cancer and that EPB41L3
may be one such target. An alternative (or combinational) therapeutic
approach to the current broad-based regimens of platinum chemothera-
pies (carboplatin and paclitaxal) might be to use gene replacement ther-
apy coupling tissue- and tumor-specific gene delivery to provide high
levels of gene expression– and tumor-targeted cell death. Recent stud-
ies have used constructs that tightly control adenoviral- and lentiviral-
driven transcription [40], and there is now promising evidence that
this approach could be successful in treating tumors. For example,
Ueda et al. [41] have shown that the expression of the nitrogen-
permease-like 2 (NPRL2) tumor-suppressor gene is restored in vivo
in an orthotopic human lung cancer model using the US Food and
Drug Administration–approved plasmid vector backbone for human
clinical application, and a phase 1 clinical trial has shown the effective-
ness of targeting the FUS1 gene in stage IV lung cancer patients [42].
In conclusion, we have shown that a functional complementation ap-
proach in ovarian cancer cell lines has identified EPB41L3 as a candidate
tumor-suppressor gene for invasive ovarian cancer. We were able to
demonstrate that the abrogation of EPB41L3 in a large series of epithelial
ovarian cancers was linked to promoter hypermethylation. We showed
functional similarities between ovarian cancer cells in which chromo-
some 18 was transferred and EPB41L3-expressing cancer cells, suggesting
that EPB41L3 is the target on chromosome 18 that is responsible for the
neoplastic suppression we observed in TOV21G cancer cells. Finally, we
show that EPB41L3 reexpression alone causes growth suppression and in-
duces apoptotic cell death in three-dimensional models of ovarian cancer.
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Base position of CpG sites on target sequence for EPB41L3.
Amplicon 1: 0-342 bp + strand
Chromosome 18, strand start: 5533584 - strand end: 5533925, span:
342 bp
CCAGGGATCCCAGGGAGGCCCCCAGGCCGGAGGCC-
GGGGCTCAGGCTCTGCGCGCCGGCCCAGCCACTACTG-
CGCCGCGGCGGGCGGAGCGGGCGGGGGGCGCGGCGCG-
CAGGCTCGGCCCGGTGGGGGTCCCGGCGAGCGG-
GAGGGCGGTTGGGGACCCCGGCCGCGCCGGGCGCGG-
GGCTCGGGATTCGGGAGACCGCGCGGCGCCGAAGC-
CACGCGTCAGCCCCACTGTCCCGCGCGCCTCGCCC-
CAGGCCTCGGGCTCTTCCTCCGCACCTCGTAAAGCCGA-
GACCCCCTCGCAGTCCCCCACTCCGAGAGGCGGAAAAGT-
TACCTGGGATCAGCAGG
Amplicon 2: 0-418 bp + strand
Chromosome 18, strand start: 5533901 - strand end: 5534318, span:
418 bp
GGAAAAGTTACCTGGGATCAGCAGGGAGCCCGGGC-
GCGCCGCGGCGTGGGGACTAGGCTCGGGCGCGCGTC-
CTCGGCGGCGGTGCGCAGGAGACTCGGGCGTGGGGAG-
GAAGCCGCAGCCCAGGGCTGCTCGCCGCTGTTCCCCC-
CGCCCCCTGTTGCAGGAGACACCGAGGCTCCGCG-
GAGCTGCGGCGGGGGCCCACGCCCAGAGACCGTGCGAG-
GAAAGCCAACCTCGTCCTGCCTGCCCTCCCAGCCG-
CGGGGGAGGGGGCCACCGCAGTACTTCAGGACAGTTA-
CATGGGCACAGCCTCCTCCGTCCTGGCGCAGGGT-
CAGGCTCCGCGGACGACGCCTGGAGACAGCTGCCAATGC-
CAATAGCTTTAGCCCTTTATTCCCACTTAGATGATG-
GCCTGGCCTCTCCAGACCCC
Amplicon 3: 0-479 bp + strand
Chromosome 18, strand start: 5533590 - strand end: 5534068, span:
479 bp
ATCCCAGGGAGGCCCCCAGGCCGGAGGCCGGGGCT-
CAGGCTCTGCGCGCCGGCCCAGCCACTACTGCGCCGC-
GGCGGGCGGAGCGGGCGGGGGGCGCGGCGCG-
CAGGCTCGGCCCGGTGGGGGTCCCGGCGAGCGG-
GAGGGCGGTTGGGGACCCCGGCCGCGCCGGGCGCG-
GGGCTCGGGATTCGGGAGACCGCGCGGCGCCGAAGC-
CACGCGTCAGCCCCACTGTCCCGCGCGCCTCGCCC-
CAGGCCTCGGGCTCTTCCTCCGCACCTCGTAAAGCCGA-
GACCCCCTCGCAGTCCCCCACTCCGAGAGGCGGAAAAGT-
TACCTGGGATCAGCAGGGAGCCCGGGCGCGCCGCGGC-
GTGGGGACTAGGCTCGGGCGCGCGTCCTCGGCGG-
CGGTGCGCAGGAGACTCGGGCGTGGGGAGGAAGCCG-
CAGCCCAGGGCTGCTCGCCGCTGTTCCCCCCGCCCCC-
TGTTGCAGGAGACACC
Table: Genomic Locations of CpG’s on the EpiTyper Target Sequence, Designed for Methylation
Analysis of EPB41L3
CpG Sequenom ID* Genomic Location (bp)
30 5533774
31 5533776
32 5533778
33 5533780
34 5533783
35 5533788
36 5533796
37 5533798
17 5534015
35 5533870
36 5533873
37 5533875
38 5533877
51 5533954
52 5533580
64 5534019
65 5534022
66 5534024
*EpiTyper assay CpG identification number, as shown in Figure 2D.
Supplementary Information 3: Verifying the Phenotypic Effects of Overexpression of EPB41L3 in Ovarian
Cancer Cell Lines
(Figures W1 to Figures W3)
Table W1. In Vitro and In Vivo Phenotype Analysis of TOV21G Ovarian Cancer Cell Lines and Five TOV21G+18 Hybrids.
In Vivo Phenotype
In Vitro Phenotype Tumor Formation (Week)§ Histopathologic Description of Excised Tissue¶
Cell Line/Hybrid
PDs* % CFE in Agar† % Invasion‡ 2 4 6 9 12
TOV21G 16.57 6.3 0.12 Peritoneal tumor implants with ascites
21G-18.1 12.49 0 0 Adipose tissue with no signs of tumor cell infiltration
21G-18.2 12.2 0 0 Normal liver tissue with no signs of tumor cell infiltration
21G-18.3 11.31 0.49 0 Normal liver tissue and pancreatic reactive mesothelium
21G-18.4 11.64 0 0 No evidence of tumor formation
21G-18.5 11.52 0 0 Tumor implants at small intestine
*Population doublings.
†Colony-forming efficiency (CFE) of cells in soft agar.
‡The percentage of cells invading through a Matrigel. For footnotes *, †, and ‡, values represent the average obtained from three independent experiments.
§Abnormal tissue excised during postmortem analysis of one animal killed at each time point, then analyzed by a histopathologist. Dark gray boxes indicate excised tissue was infiltrated by tumor cells;
light gray boxes indicate excised tissue was nonneoplastic; white boxes indicate no evidence of abnormal tissue.
¶Histopathlogical description of excised tissue.
Table W2. Table Showing Percent of Total Tumor Samples Analyzed across Three Tumor Tissue
Collections (Danish MALOVA Study, Derby City Hospital Tumor Array, and Newcastle Ovarian
Cancer Tissue Microarray) with Their Corresponding Levels of Staining for EPB41L3 Antibody.
Histologic Subtype Levels of EPB41L3 Staining*
0 1 2 3
Serous (n = 454) 66.3 19.6 9.3 4.8
Mucinous (n = 70) 61.4 17.2 14.2 7.1
Endometrioid (n = 150) 56.6 22 11.4 10
Clear cell (n = 61) 68.9 16.4 9.8 4.9
Undifferentiated (n = 38) 26.3 49.9 15.7 7.9
Papillary (n = 21) 38.0 28.5 23.8 0.4
Benign (n = 33) 24 16 6 54
*Staining values: 0, less than 5% of neoplastic cells stain positive; 1, 5% to 20%; 2, 20% to 50%;
3, more than 50%.
Figure W1. Confirming the expression of EPB41L3 after transfection into ovarian cancer cell lines TOV21G, INTOV2, and SCOV3. All three
cell lines show little or no EPB41L3 expression compared with two clones generated for each cell line expressing the EPB41L3 full-length
cDNA. Data are also shown for the two MMCT-18 hybrids generated from TOV21G, which express EPB41L3.
Figure W2. Anchorage-dependent colony formation assays of an epithelial ovarian cancer (EOC) cell line (TOV21G) transfected with a
plasmid expressing EPB41L3 (A), a GFP-labeled empty vector (control 2; B), and an alkaline phosphatase–expressing vector (control 2;
C). There are clear differences in the ability of EPB41L3-expressing EOC cells to form colonies compared with both controls as shown by
the extent of bromophenol blue–stained colonies formed after EPB41L3 transfection. There is hardly any evidence of viable cell growth
and colony formation in EPB41L3-expressing cells.
Figure W3. Anchorage-independent colony formation after overexpression of EPB41L3 in three EOC cell lines. In all three instances, ex-
pression of EPB41L3 in two-dimensional EOC cell line led to a suppression of their ability to form colonies in soft agar: (A) TOV21G+EPB41L3,
(B) TOV21G, (C) INTOV2+EPB41L3, (D) INTOV2, (E) SCOV3+EPB41L3, and (F) SCOV3.
